during treatment of Trypanosoma gambiense infection in Cote d'Ivoire. Trans R
Soc Trop Med Hyg 85:608 – 611.
Burri C and Brun R (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 90 (Suppl 1):S49 –S52.
Carter NS and Fairlamb AH (1993) Arsenical-resistant trypanosomes lack an un- usual adenosine transporter. Nature 361:173–176.
Coelho AC, Beverley SM, and Cotrim PC (2003) Functional genetic identification of
PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol 130:83–90.
Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR,
and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by
endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86:695–
698.
de Koning HP (2001) Transporters in African trypanosomes: role in drug action and
resistance. Int J Parasitol 31:512–522.
Donnelly H, Bernard EM, Rothkotter H, Gold JW, and Armstrong D (1988) Distribution of pentamidine in patients with AIDS. J Infect Dis 157:985–989.
Doua F, Miezan TW, Sanon Singaro JR, Boa Yapo F, and Baltz T (1996) The efficacy
of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense
trypanosomiasis. Am J Trop Med Hyg 55:586 –588.
Gazzin S, Strazielle N, Schmitt C, Fevre-Montange M, Ostrow JD, Tiribelli C, and
Ghersi-Egea JF (2008) Differential expression of the multidrug resistance-related
proteins ABCb1 and ABCc1 between blood-brain interfaces. J Comp Neurol 510:
497–507.
Gonza ́ lez-Martin G, Thambo S, Paulos C, Va ́ squez I, and Paredes J (1992) The
pharmacokinetics of nifurtimox in chronic renal failure. Eur J Clin Pharmacol
42:671– 673.
Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, and
Miller DW (1998) Expression of multidrug resistance-associated protein (MRP) in
brain microvessel endothelial cells. Biochem Biophys Res Commun 243:816 – 820.
Kennedy PG (2006) Diagnostic and neuropathogenesis issues in human African
trypanosomiasis. Int J Parasitol 36:505–512.
Lejon V, Legros D, Savignoni A, Etchegorry MG, Mbulamberi D, and Bu ̈ scher P
(2003) Neuro-inflammatory risk factors for treatment failure in “early second
stage” sleeping sickness patients treated with pentamidine. J Neuroimmunol
144:132–138.
Leprohon P, Le ́gare ́ D, Girard I, Papadopoulou B, and Ouellette M (2006) Modulation
of Leishmania ABC protein gene expression through life stages and among drugresistant parasites. Eukaryot Cell 5:1713–1725.
Likeufack AC, Brun R, Fomena A, and Truc P (2006) Comparison of the in vitro drug
sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa
isolated in the periods 1960 –1995 and 1999 –2004. Acta Trop 100:11–16.
Milord F, Loko L, Ethier L, Mpia B, and Pe ́pin J (1993) Eflornithine concentrations
in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei
gambiense sleeping sickness. Trans R Soc Trop Med Hyg 87:473– 477.
Murakami H, Ohkura A, Takanaga H, Matsuo H, Koyabu N, Naito M, Tsuruo T,
Ohtani H, and Sawada Y (2005) Functional characterization of adenosine transport across the BBB in mice. Int J Pharm 290:37– 44.
Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B,
Grammas P, Nedergaard M, Nutt J, et al. (2008) Strategies to advance translational research into brain barriers. Lancet Neurol 7:84 –96.
Pe ́pin J and Khonde N (1996) Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and
suramin. Trans R Soc Trop Med Hyg 90:183–186.
Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, and
Karunakara U (2007) Nifurtimox-eflornithine combination therapy for second-
